Autobahn Therapeutics, Inc. logo

Autobahn Therapeutics, Inc.

Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve.CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people.We are leveraging a deep understanding of validated human biology coupled with a brain-targeting chemistry platform to develop novel, small molecule therapies that harness the regenerative power of the human body, with an initial focus on high unmet need areas neuropsychiatry, neurodegeneration, and neuroinflammation. Our pipeline is led by ABX-002, a centrally-penetrant thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Want to join our team? Please see our open positions on the Careers page of the Autobahn website: https://autobahntx.com/careers/

Biotechnology ResearchBiotechnologyHealth CareLife ScienceTherapeutics

Autobahn Therapeutics, Inc. is a biotechnology research company headquartered in San Diego, California, United States. The team counts 34 people, up 6% over the last year. Autobahn Therapeutics, Inc. has a website drawing 3K monthly visits and most of the team based in USA.

Employees
34
+6.2% YoY
Founded
2017
Privately Held
Headquarters
San Diego
California, USA
Monthly visits
3K
+41.5% QoQ
Top country
USA
Most employees
Headcount

Employee growth

Autobahn Therapeutics, Inc. grew from ~28 employees in November 2022 to 27 by October 2024, reaching 34 by September 2026, tracked weekly in Crustdata's proprietary dataset since November 2022.

Last 3 months
-2.9%
Last 6 months
-2.9%
Last 12 months
+6.2%
Last 2 years
+21.4%
Cap table

Investors

Autobahn Therapeutics, Inc.'s 16 backers include leading firms such as ARCH Venture Partners, Alexandria Venture Investments, Biogen, and Biotechnology Value Fund.

Firms (16)
ARCH Venture PartnersAlexandria Venture InvestmentsBiogenBiotechnology Value FundBlue OwlBristol-Myers SquibbCanaan PartnersCowen Healthcare InvestmentsGT Healthcare Capital PartnersInsight PartnersInvusMonograph CapitalNewpath ManagementPfizer Venture InvestmentsS32Samsara BioCapital
Categorization

Industries & markets

Autobahn Therapeutics, Inc. is classified across the following industries, categories, and markets that Crustdata tracks for competitive analysis and sector benchmarking.

Categories
BiotechnologyHealth CareLife ScienceTherapeutics
Markets
Private
Top employee skills
PharmaceuticsClinical DevelopmentBiotechnologyClinical TrialsClinical ResearchDrug DevelopmentLeadershipGood Clinical Practice (GCP)Life SciencesProject ManagementData AnalysisMicrosoft PowerPoint

See the top Biotechnology Research companies ranked by size, growth and funding.

Growth

Autobahn Therapeutics, Inc. Growth Score

Autobahn Therapeutics, Inc. has a Crustdata Growth Score of 38 out of 100, which points to steady growth. Behind the number: headcount grew 6% year over year, web traffic grew 42% quarter over quarter, and it last raised funding 27 months ago.

38/100
Steady growth
Based on 3 of 4 growth signals
Headcount growth +6% YoY
Web traffic trend +42% QoQ
Recent funding Raised 27 months ago
FAQ

Autobahn Therapeutics, Inc. FAQs

Below are 9 of the most common questions about Autobahn Therapeutics, Inc., answered with data tracked and refreshed weekly using Crustdata's proprietary dataset.

Company Overview (4)

What industry does Autobahn Therapeutics, Inc. operate in?

Autobahn Therapeutics, Inc. operates in Biotechnology Research.

When was Autobahn Therapeutics, Inc. founded?

Autobahn Therapeutics, Inc. was founded in 2017 and is based in San Diego.

Where is Autobahn Therapeutics, Inc. headquartered?

Autobahn Therapeutics, Inc. is headquartered in San Diego, California.

Where can I find official profiles for Autobahn Therapeutics, Inc.?

Autobahn Therapeutics, Inc. can be found on their website at autobahntx.com and LinkedIn.

People & Growth (2)

How many employees does Autobahn Therapeutics, Inc. have?

Autobahn Therapeutics, Inc. has 34 employees, with 6.2% year-over-year growth.

Who are Autobahn Therapeutics, Inc.'s investors?

Autobahn Therapeutics, Inc. is backed by 16 institutional investors and 0 individual investors, including ARCH Venture Partners, Alexandria Venture Investments, Biogen, Biotechnology Value Fund, Blue Owl, and Bristol-Myers Squibb.

Markets & Operations (2)

Is Autobahn Therapeutics, Inc. publicly traded?

Autobahn Therapeutics, Inc. is privately held and is not listed on any public exchange.

What is Autobahn Therapeutics, Inc.'s website traffic?

autobahntx.com receives approximately 3K monthly visitors, with 41.5% quarter-over-quarter growth.

Growth (1)

What is Autobahn Therapeutics, Inc.'s Crustdata Growth Score?

Autobahn Therapeutics, Inc.'s growth score is 38 out of 100. The Crustdata Growth Score rates a company from 0 to 100 on how quickly it is growing, combining four signals: headcount growth, the number of open roles, web traffic trend, and how recently it last raised funding. A higher score means more of those signals are pointing up.